Medication info
Amolbika Tablet 5/40 mg

Amolbika Tablet 5/40 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
HanKook HyuTex Pharmaceuticals Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP packaging x 3)
Approval status
Active

MFDS item code 201404735 · Approved 2014.10.15 · Insurance code 649102470

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60 mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not be administered this medicine, under Precautions for Use.) ○ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
○ Pediatrics: The safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
HanKook HyuTex Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine or Olmesartan Medoxomil is used when blood pressure is not adequately controlled with monotherapy in patients with essential hypertension. These medications effectively lower blood pressure and help reduce the risk of cardiovascular complications. They contribute to maintaining overall health by improving the patient's blood pressure status. Therefore, this drug plays an important role in the treatment of hypertension.

How to take

Adult dose

This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60 mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not be administered this medicine, under Precautions for Use.) ○ Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

○ Pediatrics: The safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to the components in this drug or similar class medications, those who are pregnant or breastfeeding, patients with severe liver or kidney diseases, severe aortic stenosis, bile duct obstruction, kidney dialysis patients, patients in shock, certain diabetic patients, and those with kidney dysfunction should not take this medication. Patients with low blood pressure due to lack of fluids or salts should be cautious as they may experience symptoms of low blood pressure when taking this drug, and appropriate treatment may be needed if blood pressure drops too low. The vasodilating effects may cause acute hypotension, so especially in patients with severe aortic stenosis, careful administration is necessary. Patients with heart disease, coronary artery disease, or congestive heart failure should be cautious, as symptoms may worsen with this medication. Patients whose kidney function is sensitive to medications should be monitored for changes in kidney function, and those with decreased liver function should also take this drug with caution. Various side effects may occur with this medication. Common symptoms include dizziness, headache, low blood pressure, orthostatic hypotension, palpitations, nausea, vomiting, rash, swelling, and rarely serious side effects have been reported. During pregnancy, the risk of fetal harm is increased, so discontinuation of the medication is essential, and for those breastfeeding, as this medication can be transmitted through breast milk, it is recommended to either discontinue breastfeeding or the medication. Safety and efficacy in pediatric patients under 18 years have not been established, so use is not recommended. Elderly patients may have increased drug concentrations due to decreased kidney and liver function, so it is essential to start with a low dose and proceed with caution. In cases of overdose, severe hypotension, vasodilation, and tachycardia can occur, so immediate monitoring of cardiac and respiratory status in a medical facility and appropriate treatment are required. This medication may enhance blood pressure-lowering effects when taken with grapefruit juice, hence concurrent use should be avoided. Additionally, when used with other antihypertensive drugs or potassium-sparing diuretics or potassium supplements, blood potassium levels may increase, necessitating regular blood tests. When storing this medication, it is crucial to keep it out of reach of children and avoid moisture, heat, and direct sunlight.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • hypesthesia
  • syncope
Show 81 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • weakness
  • facial swelling
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • herpes zoster
  • double vision
  • insomnia
  • weakness
  • vascular edema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • elevated serum creatinine
  • hair loss
  • itching
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • hypotension
  • tachycardia
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advised to maintain a storage temperature between 1 and 30 degrees Celsius, as this helps to preserve the medication's effectiveness.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP packaging x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.